Cystic fibrosis microbiology: Advances in antimicrobial therapy

Journal of Cystic Fibrosis

Volumn 14, Issue 5, 2015, Pages 551-560

  Waters, Valerie ^a   Smyth, Alan ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Antimicrobials; Cystic fibrosis

Indexed keywords

ALGINIC ACID; AMIKACIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; COLISTIMETHATE; COLISTIN; GALLIUM; LEVOFLOXACIN; OLIGOSACCHARIDE; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BIOFILM; CYSTIC FIBROSIS; DRY POWDER; HUMAN; IMMUNIZATION; LUNG DISEASE; LUNG FUNCTION; LUNG INFECTION; MICROBIOME; NEPHROTOXICITY; OTOTOXICITY; PATIENT COMPLIANCE; PSEUDOMONAS AERUGINOSA; REVIEW; DRUG ADMINISTRATION ROUTE; MICROBIOLOGY; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG ADMINISTRATION ROUTES; HUMANS; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84940960251     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2015.02.005     Document Type: Review

References (92)

1. Hurley M.N., McKeever T.M., Prayle A.P., Fogarty A.W., Smyth A.R. Rate of improvement of CF life expectancy exceeds that of general population-observational death registration study. J Cyst Fibros 2014, 13(4):410-415.
2. McCoy K.S., Quittner A.L., Oermann C.M., Gibson R.L., Retsch-Bogart G.Z., Montgomery A.B. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008, 178(9):921-928.
3. Retsch-Bogart G.Z., Quittner A.L., Gibson R.L., Oermann C.M., McCoy K.S., Montgomery A.B., et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009, 135(5):1223-1232.
4. Wainwright C.E., Quittner A.L., Geller D.E., Nakamura C., Wooldridge J.L., Gibson R.L., et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros 2011, 10(4):234-242.
5. Assael B.M., Pressler T., Bilton D., Fayon M., Fischer R., Chiron R., et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 2013, 12(2):130-140.
6. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340(1):23-30.
7. Tullis D.E., Burns J.L., Retsch-Bogart G.Z., Bresnik M., Henig N.R., Lewis S.A., et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros 2014, 13(3):296-305.
8. Yu Q., Griffin E.F., Moreau-Marquis S., Schwartzman J.D., Stanton B.A., O'Toole G.A. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. J Antimicrob Chemother 2012, 67(11):2673-2681.
9. Mandell G.L., BJ, Dolin R. Principles and practice of infectious diseases 2010, Elsevier Churchill Livingstone, Philadelphia. 7th ed.
10. Worlitzsch D., Tarran R., Ulrich M., Schwab U., Cekici A., Meyer K.C., et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002, 109(3):317-325.
11. King P., Citron D.M., Griffith D.C., Lomovskaya O., Dudley M.N. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. Diagn Microbiol Infect Dis 2010, 66(2):181-186.
12. King P., Lomovskaya O., Griffith D.C., Burns J.L., Dudley M.N. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother 2010, 54(1):143-148.
13. Tsivkovskii R., Sabet M., Tarazi Z., Griffith D.C., Lomovskaya O., Dudley M.N. Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections. FEMS Immunol Med Microbiol 2011, 61(2):141-146.
14. Geller D.E., Flume P.A., Griffith D.C., Morgan E., White D., Loutit J.S., et al. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother 2011, 55(6):2636-2640.
15. Geller D.E., Flume P.A., Staab D., Fischer R., Loutit J.S., Conrad D.J. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011, 183(11):1510-1516.
16. Elborn J.S., Geller D.E., Conrad D., Aaron S.D., Smyth A.R., Fischer R., et al. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros 2015, 14(4):507-514.
17. Parkins M.D., Elborn J.S. Tobramycin inhalation powder: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respir Med 2011, 5(5):609-622.
18. Geller D.E., Konstan M.W., Smith J., Noonberg S.B., Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007, 42(4):307-313.
19. Konstan M.W., Geller D.E., Minic P., Brockhaus F., Zhang J., Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2010.
20. Konstan M.W., Flume P.A., Kappler M., Chiron R., Higgins M., Brockhaus F., et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011, 10(1):54-61.
21. Schuster A., Haliburn C., Doring G., Goldman M.H. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013, 68(4):344-350.
22. Clancy J. Clinical trials of lipid-associated aerosolized amikacin: the Arikace story. Pediatr Pulmonol 2009, 44:109-212.
23. Meers P., Neville M., Malinin V., Scotto A.W., Sardaryan G., Kurumunda R., et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008, 61(4):859-868.
24. Okusanya O.O., Bhavnani S.M., Hammel J., Minic P., Dupont L.J., Forrest A., et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic Pseudomonal infection. Antimicrob Agents Chemother 2009, 53(9):3847-3854.
25. Clancy J.P., Dupont L., Konstan M.W., Billings J., Fustik S., Goss C.H., et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013, 68(9):818-825.
26. Clinical Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing 2012, Wayne, PA, CLSI.
27. Chmiel J.F., Aksamit T.R., Chotirmall S.H., Dasenbrook E.C., Elborn J.S., LiPuma J.J., et al. Antibiotic management of lung infections in cystic fibrosis: part I. The microbiome, MRSA, Gram-Negative bacteria, and multiple infections. Ann Am Thorac Soc 2014, 11(8):1298-1306.
28. Govan J.R. Multidrug-resistant pulmonary infection in cystic fibrosis-what does 'resistant' mean?. J Med Microbiol 2006, 55(Pt 12):1615-1617.
29. Hoffman L.R., D'Argenio D.A., MacCoss M.J., Zhang Z., Jones R.A., Miller S.I. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005, 436(7054):1171-1175.
30. Imperi F., Leoni L., Visca P. Antivirulence activity of azithromycin in Pseudomonas aeruginosa. Front Microbiol 2014, 5:178.
31. Smith A.L., Fiel S.B., Mayer-Hamblett N., Ramsey B., Burns J.L. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003, 123(5):1495-1502.
32. Moskowitz S.M., Emerson J.C., McNamara S., Shell R.D., Orenstein D.M., Rosenbluth D., et al. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol 2011, 46(2):184-192.
33. Mayer-Hamblett N., Aitken M.L., Accurso F.J., Kronmal R.A., Konstan M.W., Burns J.L., et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007, 175(8):822-828.
34. Henry R.L., Mellis C.M., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992, 12(3):158-161.
35. Waters V., Yau Y., Prasad S., Lu A., Atenafu E., Crandall I., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011, 183(5):635-640.
36. Dasenbrook E.C., Checkley W., Merlo C.A., Konstan M.W., Lechtzin N., Boyle M.P. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010, 303(23):2386-2392.
37. Hadjiliadis D., Steele M.P., Chaparro C., Singer L.G., Waddell T.K., Hutcheon M.A., et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007, 26(8):834-838.
38. Aitken M.L., Limaye A., Pottinger P., Whimbey E., Goss C.H., Tonelli M.R., et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012, 185(2):231-232.
39. Esther C.R., Henry M.M., Molina P.L., Leigh M.W. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005, 40(1):39-44.
40. Choi G.E., Shin S.J., Won C.J., Min K.N., Oh T., Hahn M.Y., et al. Macrolide treatment for Mycobacterium abscessus and M. massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012, 186(9):917-925.
41. van Ingen J., Boeree M.J., van Soolingen D., Mouton J.W. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012, 15(3):149-161.
42. Madan J.C., Koestler D.C., Stanton B.A., Davidson L., Moulton L.A., Housman M.L., et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. MBio 2012, 3(4).
43. Sherrard L.J., Tunney M.M., Elborn J.S. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet 2014, 384(9944):703-713.
44. Tunney M.M., Field T.R., Moriarty T.F., Patrick S., Doering G., Muhlebach M.S., et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008, 177(9):995-1001.
45. Sherrard L.J., Graham K.A., McGrath S.J., McIlreavey L., Hatch J., Muhlebach M.S., et al. Antibiotic resistance in Prevotella species isolated from patients with cystic fibrosis. J Antimicrob Chemother 2013, 68(10):2369-2374.
46. Zhao J., Schloss P.D., Kalikin L.M., Carmody L.A., Foster B.K., Petrosino J.F., et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A 2012, 109(15):5809-5814.
47. Zhao J., Murray S., Lipuma J.J. Modeling the impact of antibiotic exposure on human microbiota. Sci Rep 2014, 4:4345.
48. Price K.E., Hampton T.H., Gifford A.H., Dolben E.L., Hogan D.A., Morrison H.G., et al. Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome 2013, 1(1):27.
49. Fodor A.A., Klem E.R., Gilpin D.F., Elborn J.S., Boucher R.C., Tunney M.M., et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One 2012, 7(9):e45001.
50. Carmody L.A., Zhao J., Schloss P.D., Petrosino J.F., Murray S., Young V.B., et al. Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann Am Thorac Soc 2013, 10(3):179-187.
51. Smith D.J., Badrick A.C., Zakrzewski M., Krause L., Bell S.C., Anderson G.J., et al. Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. Eur Respir J 2014, 44(4):922-930.
52. Zemanick E.T., Harris J.K., Wagner B.D., Robertson C.E., Sagel S.D., Stevens M.J., et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoS One 2013, 8(4):e62917.
53. Tunney M.M., Klem E.R., Fodor A.A., Gilpin D.F., Moriarty T.F., McGrath S.J., et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 2011, 66(7):579-584.
54. Hurley M.N., Forrester D.L., Smyth A.R. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Cochrane Database Syst Rev 2010, 10:CD008037.
55. Kaneko Y., Thoendel M., Olakanmi O., Britigan B.E., Singh P.K. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest 2007, 117(4):877-888.
56. Halwani M., Yebio B., Suntres Z.E., Alipour M., Azghani A.O., Omri A. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J Antimicrob Chemother 2008, 62(6):1291-1297.
57. Taylor K., McCullough B., Clarke D.J., Langley R.J., Pechenick T., Hill A., et al. Covalent dimer species of beta-defensin Defr1 display potent antimicrobial activity against multidrug-resistant bacterial pathogens. Antimicrob Agents Chemother 2007, 51(5):1719-1724.
58. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003, 3(9):710-720.
59. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1999, 1462(1-2):55-70.
60. Saiman L., Tabibi S., Starner T.D., San Gabriel P., Winokur P.L., Jia H.P., et al. Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Antimicrob Agents Chemother 2001, 45(10):2838-2844.
61. Caraher E.M., Gumulapurapu K., Taggart C.C., Murphy P., McClean S., Callaghan M. The effect of recombinant human lactoferrin on growth and the antibiotic susceptibility of the cystic fibrosis pathogen Burkholderia cepacia complex when cultured planktonically or as biofilms. J Antimicrob Chemother 2007, 60(3):546-554.
62. Guina T., Yi E.C., Wang H., Hackett M., Miller S.I. A PhoP-regulated outer membrane protease of Salmonella enterica serovar typhimurium promotes resistance to alpha-helical antimicrobial peptides. J Bacteriol 2000, 182(14):4077-4086.
63. Shafer W.M., Qu X., Waring A.J., Lehrer R.I. Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc Natl Acad Sci U S A 1998, 95(4):1829-1833.
64. Singh P.K., Schaefer A.L., Parsek M.R., Moninger T.O., Welsh M.J., Greenberg E.P. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000, 407(6805):762-764.
65. Drenkard E., Ausubel F.M. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002, 416(6882):740-743.
66. Govan J.R., Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996, 60(3):539-574.
67. Ryall B., Carrara M., Zlosnik J.E., Behrends V., Lee X., Wong Z., et al. The mucoid switch in Pseudomonas aeruginosa represses quorum sensing systems and leads to complex changes to stationary phase virulence factor regulation. PLoS One 2014, 9(5):e96166.
68. Prince A.S. Biofilms, antimicrobial resistance, and airway infection. N Engl J Med 2002, 347(14):1110-1111.
69. Camara M., Williams P., Hardman A. Controlling infection by tuning in and turning down the volume of bacterial small-talk. Lancet Infect Dis 2002, 2(11):667-676.
70. Mah T.F., Pitts B., Pellock B., Walker G.C., Stewart P.S., O'Toole G.A. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003, 426(6964):306-310.
71. Khan S., Tondervik A., Sletta H., Klinkenberg G., Emanuel C., Onsoyen E., et al. Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics. Antimicrob Agents Chemother 2012, 56(10):5134-5141.
72. Rasmussen T.B., Bjarnsholt T., Skindersoe M.E., Hentzer M., Kristoffersen P., Kote M., et al. Screening for quorum-sensing inhibitors (QSI) by use of a novel genetic system, the QSI selector. J Bacteriol 2005, 187(5):1799-1814.
73. Bjarnsholt T., Jensen P.O., Rasmussen T.B., Christophersen L., Calum H., Hentzer M., et al. Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology 2005, 151(Pt 12):3873-3880.
74. Smyth A.R., Cifelli P.M., Ortori C.A., Righetti K., Lewis S., Erskine P., et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis-a pilot randomized controlled trial. Pediatr Pulmonol 2010, 45(4):356-362.
75. Wallock-Richards D., Doherty C.J., Doherty L., Clarke D.J., Place M., Govan J.R., et al. Garlic revisited: antimicrobial activity of allicin-containing garlic extracts against Burkholderia cepacia complex. PLoS One 2014, 9(12):e112726.
76. Bodewits K., Raetz C.R., Govan J.R., Campopiano D.J. Antimicrobial activity of CHIR-090, an inhibitor of lipopolysaccharide biosynthesis, against the Burkholderia cepacia complex. Antimicrob Agents Chemother 2010, 54(8):3531-3533.
77. Moore R., Kyd J.M., Carzino R., Armstrong D., Grimwood K., Otczyk D.C., et al. Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection. Hum Vaccin Immunother 2013, 9(3):506-514.
78. Zuercher A.W., Horn M.P., Que J.U., Ruedeberg A., Schoeni M.H., Schaad U.B., et al. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol Med Microbiol 2006, 47(2):302-308.
79. Campodonico V.L., Llosa N.J., Bentancor L.V., Maira-Litran T., Pier G.B. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice. Infect Immun 2011, 79(8):3455-3464.
80. Langford D.T., Hiller J. Prospective, controlled study of a polyvalent Pseudomonas vaccine in cystic fibrosis-three year results. Arch Dis Child 1984, 59(12):1131-1134.
81. Doring G., Meisner C., Stern M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci U S A 2007, 104(26):11020-11025.
82. Doring G. Vaccine development for patients with cystic fibrosis. Expert Rev Vaccines 2012, 11(3):259-261.
83. Johansen H.K., Gotzsche P.C. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2013, 6:CD001399.
84. Bumann D., Behre C., Behre K., Herz S., Gewecke B., Gessner J.E., et al. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers. Vaccine 2010, 28(3):707-713.
85. Nilsson E., Larsson A., Olesen H.V., Wejaker P.E., Kollberg H. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol 2008, 43(9):892-899.
86. Briesacher B.A., Quittner A.L., Saiman L., Sacco P., Fouayzi H., Quittell L.M. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med 2011, 11:5.
87. Latchford G., Duff A., Quinn J., Conway S., Conner M. Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ Couns 2009, 75(1):141-144.
88. Daniels T., Goodacre L., Sutton C., Pollard K., Conway S., Peckham D. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011, 140(2):425-432.
89. McNamara P.S., McCormack P., McDonald A.J., Heaf L., Southern K.W. Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. J Cyst Fibros 2009, 8(4):258-263.
90. Smyth A., Tan K.H., Hyman-Taylor P., Mulheran M., Lewis S., Stableforth D., et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005, 365(9459):573-578.
91. Russo M.J., Davies R.R., Hong K.N., Iribarne A., Kawut S., Bacchetta M., et al. Who is the high-risk recipient? Predicting mortality after lung transplantation using pretransplant risk factors. J Thorac Cardiovasc Surg 2009, 138(5):1234-1238. [e1].
92. Fleischer E. A teenager with tinnitus: not the "usual suspect". Pediatr Pulmonol 2013.